Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 4/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621600 | 0.94 | LMNA (0.62) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL7626878 | 0.94 | LMNA (0.58) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL797051 | 0.93 | LMNA (0.63) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL16146712 | 0.81 | ADORA3 (0.56) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL16146850 | 0.81 | LMNA (0.54) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL7111204 | 0.81 | XDH (0.62) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL3396378 | 0.78 | PDPK1 (0.61) | PDPK1GDACDK1BRAFCDK2 | |
| SCHEMBL8563173 | 0.78 | CDK1 (0.58) | PDPK1GDACDK1BRAFCDK2 | |
| SCHEMBL3133575 | 0.78 | ADORA3 (0.50) | LMNAHTTPAK1ADORA3ADORA2A | |
| SCHEMBL164700 | 0.77 | XDH (0.65) | PDPK1GDACDK1BRAFCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| WO-2008025160-A1 | OXEPANE NUCLEOSIDES AND OLIGONUCLEOTIDES, USES THEREOF AND METHODS OF MAKING THE SAME | MCGILL UNIVERSITY (CA) | 2008-03-06 | — | — | WO | claimed |
| US-6444656-B1 | (5R)-(2-AMINO-6-HYDROXY-PURIN-9-YLMETHYL)-(4R)-AZIDO-TETRAHYDR O-FURAN-(2S)- PHOSPHONATE; PARTICULARLY AGAINST HIV AND/OR HBV INFECTIONS | BIOCHEM PHARMA, INC. (CA) | 2002-09-03 | — | — | US | claimed |
| EP-1032573-A1 | PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | claimed |
| WO-1999024431-A1 | PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| WO-1999021861-A1 | PROCESS FOR PREPARING A CHIRAL NUCLEOSIDE ANALOGUE | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | WO | claimed |
| WO-1998030563-A1 | 2-HYDROXYMETHYLCYCLOPROPYLI- DENEMETHYLPURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-07-16 | — | — | WO | claimed |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240182945-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | TETS VICTOR (US) | 2024-06-06 | — | — | US | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-9572898-B2 | Functionalized fluorine containing phthalocyanine molecules | SETON HALL UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| EP-0648218-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-19 | — | — | EP | disclosed |
| EP-0286425-B1 | Therapeutic nucleosides | WELLCOME FOUND (GB) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994001443-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| US-5185437-A | 6-substituted 2',3'-dideoxypurine nucleosides; treatment for human immunodeficiency virus and heptatis b virus | BURROUGHS WELLCOME CO. (US) | 1993-02-09 | — | — | US | disclosed |
| US-5068320-A | 2-amino-6-(cyclopropylamino)purine-9-β-D-2',3'-dideoxyribofuranoside and its pharmaceutically acceptable salts | BURROUGHS WELLCOME CO. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0421819-A1 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-04-10 | — | — | EP | disclosed |
| EP-0286425-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | LMNA 599/4885HTT 3291/4885PAK1 197/4885 |
| US-20260071249-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | EIF2A, EIF6, TUFM | LMNA 2991/4885HTT 393/4885PAK1 1106/4885 |
| US-20260071247-A1 | PRODUCTS FOR REGULATION OF EUKARYOTIC AND MICROBIAL CELLS GROWTH | AMPD1, TUFM, AMPD3 | LMNA 2516/4885HTT 687/4885PAK1 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.